CRISPR Therapeutics AG.
CRSP.US | Research and experimental development on natural sciences and engineering
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing gene-based medicines using its proprietary CRISPR/Cas9 platform. The company's primary focus is on developing therapies for serious diseases with unmet medical needs, including hemoglobinopathies, oncology, regenerative medi...Show More
Better Health for All
0
No evidence available to assess CRISPR Therapeutics AG on Better Health for All.
Fair Money & Economic Opportunity
0
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing gene-based medicines.
1
The company's core business does not involve offering lending, deposit, or other financial services to consumers.
2
Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its operations.
Fair Pay & Worker Respect
0
No evidence available to assess CRISPR Therapeutics AG on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific data points were provided in the articles regarding CRISPR Therapeutics AG's performance on fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, share of spend on high-risk materials, or supplier diversity spend.
1
Honest & Fair Business
0
The company has a Code of Business Conduct and Ethics, last amended in December 2023, which includes a whistleblower policy.
1
Employees can report violations anonymously through a third-party managed online platform or phone line.
2
The company forbids retaliation against those who report suspected misconduct in good faith and explicitly states that the code does not limit the right to report unlawful conduct to government agencies or to receive awards under whistleblower provisions.
3
CRISPR Therapeutics has a U.S. Foreign Corrupt Practices Act and Anti-Corruption Policy, prohibiting bribes, kickbacks, or other improper payments.
4
The anonymous and phone reporting channels for potential Code violations are managed by a third party.
5
Kind to Animals
-70
CRISPR Therapeutics AG is not certified cruelty-free.
1
The company conducts animal testing for preclinical research, which includes studies to evaluate efficacy and toxicity in animals.
2
While the company's preclinical tests must comply with FDA's Good Laboratory Practice (GLP) regulations, no specific details on the scope and enforcement of its animal testing policy are provided, nor are there any measurable goals for reduction.
3
There is no data on the number of animals used annually by CRISPR Therapeutics AG, but the company's preclinical testing involves animal studies.
4
No War, No Weapons
0
No specific, concrete data points were found in the provided article to assess CRISPR Therapeutics AG against the 'No War, No Weapons' ethical value KPIs. The article mentions the Defense Department funding research into making CRISPR safer, and the technology's potential applications for bioterrorism threats and mosquito gene drives, but this information does not directly provide quantitative data for any of the defined KPIs for CRISPR Therapeutics AG itself.
1
Planet-Friendly Business
0
The provided articles do not contain specific, quantitative data points for any of the Planet-Friendly Business KPIs related to CRISPR Therapeutics AG's operational environmental performance. While some articles discuss the potential environmental benefits of CRISPR technology in areas like drought-resistant crops, methane reduction in cattle, and wastewater treatment, this relates to the company's product applications and research, not its own corporate environmental footprint.
1
Article 4 explicitly states that "No Waste Management data disclosed by CRISPR Therapeutics."
2
Other articles contain general statements about incorporating LEED design standards or being dedicated to reducing carbon footprint, but lack specific percentages, emissions figures, or verified targets required by the rubric.
3
External ratings or acknowledgments of environmental laws are not direct evidence for KPI scoring.
Respect for Cultures & Communities
0
The provided articles do not contain specific, quantitative data points for any of the KPIs related to 'Respect for Cultures & Communities'. While general corporate responsibility and patient advocacy are mentioned, there is no evidence regarding formal partnerships with indigenous or local community groups, revenue reinvested locally, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, FPIC participation rates, community governance inclusion, cultural preservation investment, local procurement, indigenous supplier engagement, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.
1
General statements about supporting charities are made, but without specific financial contributions or percentages, they cannot be used to score quantitative KPIs.
2
Safe & Smart Tech
0
No evidence available to assess CRISPR Therapeutics AG on Safe & Smart Tech.
Zero Waste & Sustainable Products
-40
The company's operations involve the use of hazardous and flammable materials, including chemicals and biological materials, and produce hazardous waste products.
1
CRISPR Therapeutics generally anticipates contracting with third parties for the disposal of these materials and wastes.
2
A fully digital control system manages environmental, health, and safety (EHS) data at its facility.
3